Condition

IDH1-Mutated Malignancies clinical trials and research

• 2Clinical trials
• 6Countries

All recruiting trials (2)

• Olutasidenib combined with targeted agents for relapsed IDH1‑mutated myeloid cancers with activated signaling mutations

  This trial tests whether adding olutasidenib to targeted drugs or low‑intensity chemotherapy helps adults with relapsed or refractory IDH1‑mutated myeloid malignancies that also have an activated signaling mutation.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Miami, Florida and 1 other locations · NCT07032727

• Ivosidenib for adults with IDH1‑mutated cancers and liver or kidney impairment.

  This will test ivosidenib in adults with IDH1‑mutated cancers who have liver or kidney impairment to see how the drug is absorbed, processed, and tolerated.

  Recruiting at 17 sites Phase 1 Servier · Atlanta, Georgia and 19 other locations · NCT07006688

Related topics

Quick answers

How many IDH1-Mutated Malignancies clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in United States (2 trials), Australia (1 trial), Brazil (1 trial), Czechia (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →